Reaua Genital Warts

Description

No description information is available for the specified drug.

Uses and Indications

This drug is indicated for the removal of common warts, characterized by a rough, cauliflower-like appearance.

Dosage and Administration

Healthcare professionals are advised to follow the outlined procedure for the application of the medication to ensure optimal results.

The affected area should be washed thoroughly, and soaking in warm water for approximately 5 minutes may facilitate this process. After cleansing, the area must be dried completely to ensure proper adhesion of the medication.

A small amount of the medication should be applied directly to cover each wart. It is important to allow the application to dry completely before proceeding with any additional steps or coverings.

This application should be repeated twice daily as needed, with a maximum treatment duration of up to 12 weeks. Regular monitoring of the treatment area is recommended to assess the effectiveness and any potential side effects.

Contraindications

Use is contraindicated in the following situations:

Application on irritated or infected skin, or on areas exhibiting redness, is not recommended due to the potential for exacerbating the condition.

Patients with diabetes or poor blood circulation should avoid use, as these conditions may increase the risk of adverse effects.

Additionally, the product should not be applied to birthmarks, warts with hair growth, or moles, as these may present a risk of irritation or other complications.

Warnings and Precautions

For external use only; contact with the eyes must be avoided. In the event that the product comes into contact with the eyes, it is imperative to rinse thoroughly with water for a minimum of 15 minutes. Additionally, users should refrain from inhaling vapors associated with the product to prevent respiratory irritation.

Healthcare professionals should advise patients who are pregnant or breastfeeding to consult with a qualified health professional prior to using this product to ensure safety for both the mother and child.

In cases of accidental ingestion, immediate medical assistance should be sought, or the local Poison Control Center should be contacted without delay.

Patients are also instructed to discontinue use and consult a physician if discomfort persists, as this may indicate an adverse reaction that requires further evaluation.

Side Effects

Patients using this product should be aware of several important warnings and recommendations regarding adverse reactions. The product is intended for external use only, and contact with the eyes should be strictly avoided. In the event that the product comes into contact with the eyes, it is advised to rinse thoroughly with water for at least 15 minutes. Additionally, patients should avoid inhaling vapors associated with the product.

If any discomfort persists after use, patients are advised to stop using the product and consult a healthcare professional for further guidance. This precaution is essential to ensure the safety and well-being of individuals using the product.

Drug Interactions

There are currently no documented drug interactions associated with this medication. Additionally, there are no known interactions with laboratory tests. As such, no specific recommendations for dosage adjustments or monitoring are warranted at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Reaua Genital Warts (salicylic acid 17% genital warts). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep this medication out of reach of children. In the event of accidental ingestion, immediate medical assistance should be sought, or contact with a Poison Control Center is recommended.

Geriatric Use

There is no specific information available regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. It is advisable to monitor these patients closely for any adverse effects or changes in efficacy.

Pregnancy

Pregnant patients and those who are breastfeeding should consult a healthcare professional prior to using this medication. It is essential to evaluate the potential risks and benefits in these populations to ensure the safety of both the mother and the fetus or infant.

Lactation

Lactating mothers are advised to consult a health professional prior to using this medication. There is currently no available data regarding the excretion of this medication in human breast milk or its effects on breastfed infants. Therefore, healthcare providers should carefully evaluate the potential risks and benefits when considering treatment for lactating patients.

Renal Impairment

There is no information available regarding dosage adjustments, special monitoring, or safety considerations for patients with renal impairment. Healthcare professionals should exercise caution and consider the lack of specific guidance when prescribing to patients with reduced kidney function.

Hepatic Impairment

There is no information available regarding the use of this medication in patients with hepatic impairment. Consequently, there are no dosage adjustments, special monitoring requirements, or precautions specified for individuals with compromised liver function. Healthcare professionals should exercise caution and consider the lack of data when prescribing this medication to patients with liver problems.

Overdosage

In the absence of specific overdosage information, it is essential for healthcare professionals to remain vigilant regarding the potential for overdose with this medication. In cases where an overdose is suspected, immediate medical attention should be sought.

Healthcare providers are advised to monitor patients closely for any signs or symptoms that may indicate an overdose. These may include, but are not limited to, altered mental status, cardiovascular instability, or gastrointestinal disturbances.

Management of an overdose should be guided by the clinical presentation of the patient. Supportive care is paramount, and symptomatic treatment should be initiated as necessary. It is recommended that healthcare professionals consult local poison control centers or relevant toxicology resources for guidance on specific management protocols.

In summary, while no specific overdosage information is available, healthcare professionals should exercise caution and be prepared to act swiftly in the event of an overdose scenario.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the use of the compound in these contexts.

Postmarketing Experience

No postmarketing experience details are provided in the insert.

Patient Counseling

Healthcare providers should advise patients to seek immediate medical help or contact a Poison Control Center if the product is swallowed.

Patients should be informed that the product should not be applied to irritated or infected skin, or to reddened areas, particularly if they are diabetic or have poor blood circulation. Additionally, it should not be used on birthmarks, warts with hair growth, or moles.

Healthcare providers should instruct patients to stop using the product and consult a doctor if discomfort persists after application.

For patients who are pregnant or breastfeeding, it is essential to recommend consulting a health professional before using the product to ensure safety for both the patient and the child.

Storage and Handling

The product is supplied in a tube format, with specific handling and storage requirements to ensure its integrity and efficacy. It should be stored at room temperature, away from direct light exposure. To maintain the product's quality, it is essential to keep the tube tightly closed when not in use. Additionally, any unused product should be discarded after opening if it is not utilized within the specified time frame.

Additional Clinical Information

No further data are available.

Drug Information (PDF)

This file contains official product information for Reaua Genital Warts, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)